Kolltan Pharmaceuticals, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘Kolltan Pharmaceuticals, Inc. – Product Pipeline Review – 2016’, provides an overview of the Kolltan Pharmaceuticals, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Kolltan Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Kolltan Pharmaceuticals, Inc.

The report provides overview of Kolltan Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Kolltan Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Kolltan Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Kolltan Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Kolltan Pharmaceuticals, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Kolltan Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Kolltan Pharmaceuticals, Inc. Snapshot 5

Kolltan Pharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

Kolltan Pharmaceuticals, Inc. - Research and Development Overview 6

Key Therapeutic Areas 6

Kolltan Pharmaceuticals, Inc. - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Kolltan Pharmaceuticals, Inc. - Pipeline Products Glance 11

Kolltan Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 11

Phase I Products/Combination Treatment Modalities 11

Kolltan Pharmaceuticals, Inc. - Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Kolltan Pharmaceuticals, Inc. - Drug Profiles 14

KTN-0158 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

KTN-3379 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

KIT-SG3227 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

KTN-0182A 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Monoclonal Antibody Conjugate to Antagonize ALK Receptor for Oncology 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Monoclonal Antibody Conjugate to Inhibit Axl for Cancer, Inflammation and Infection 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibody Conjugate to Target ErbB-3 for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody to Inhibit c-MET for Cancer 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Monoclonal Antibody to Inhibit DDR for Cancer and Osteoporosis 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibody to Inhibit FGFR4 for Cancer 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibody to Inhibit MERTK for Cancer, Inflammation and Infection 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibody to Inhibit RON for Cancer 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Kolltan Pharmaceuticals, Inc. - Pipeline Analysis 29

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Target 29

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 30

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 31

Kolltan Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 32

Kolltan Pharmaceuticals, Inc. - Recent Pipeline Updates 33

Kolltan Pharmaceuticals, Inc. - Locations And Subsidiaries 36

Head Office 36

Other Locations & Subsidiaries 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Kolltan Pharmaceuticals, Inc., Key Information 5

Kolltan Pharmaceuticals, Inc., Key Facts 5

Kolltan Pharmaceuticals, Inc. – Pipeline by Indication, 2016 7

Kolltan Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 9

Kolltan Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 10

Kolltan Pharmaceuticals, Inc. – Phase I, 2016 11

Kolltan Pharmaceuticals, Inc. – Preclinical, 2016 12

Kolltan Pharmaceuticals, Inc. – Discovery, 2016 13

Kolltan Pharmaceuticals, Inc. – Pipeline by Target, 2016 29

Kolltan Pharmaceuticals, Inc. – Pipeline by Route of Administration, 2016 30

Kolltan Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 31

Kolltan Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 32

Kolltan Pharmaceuticals, Inc. – Recent Pipeline Updates, 2016 33

Kolltan Pharmaceuticals, Inc., Subsidiaries 36

List of Figures

List of Figures

Kolltan Pharmaceuticals, Inc. – Pipeline by Top 10 Indication, 2016 7

Kolltan Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2016 9

Kolltan Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2016 10

Kolltan Pharmaceuticals, Inc. – Pipeline by Target, 2016 29

Kolltan Pharmaceuticals, Inc. – Pipeline by Molecule Type, 2016 31

Kolltan Pharmaceuticals, Inc. – Pipeline Products by Mechanism of Action, 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports